PL3570940T3 - Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x - Google Patents
Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu xInfo
- Publication number
- PL3570940T3 PL3570940T3 PL18741607.8T PL18741607T PL3570940T3 PL 3570940 T3 PL3570940 T3 PL 3570940T3 PL 18741607 T PL18741607 T PL 18741607T PL 3570940 T3 PL3570940 T3 PL 3570940T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- fragile
- syndrome
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448595P | 2017-01-20 | 2017-01-20 | |
| PCT/US2018/014169 WO2018136600A1 (en) | 2017-01-20 | 2018-01-18 | Use of pridopidine for the treatment of fragile x syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3570940T3 true PL3570940T3 (pl) | 2024-06-17 |
Family
ID=62908348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18741607.8T PL3570940T3 (pl) | 2017-01-20 | 2018-01-18 | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11234973B2 (pl) |
| EP (1) | EP3570940B1 (pl) |
| JP (1) | JP7114604B2 (pl) |
| CN (1) | CN110505902B (pl) |
| AU (1) | AU2018210145B2 (pl) |
| BR (1) | BR112019015000A2 (pl) |
| CA (1) | CA3050700C (pl) |
| DK (1) | DK3570940T3 (pl) |
| ES (1) | ES2972205T3 (pl) |
| HU (1) | HUE068300T2 (pl) |
| IL (1) | IL268125B2 (pl) |
| PL (1) | PL3570940T3 (pl) |
| WO (1) | WO2018136600A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| WO2021141426A1 (ko) * | 2020-01-08 | 2021-07-15 | 건국대학교 글로컬산학협력단 | 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6472736A (en) | 1987-09-14 | 1989-03-17 | Toshiba Corp | Mri apparatus |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| MX2007004216A (es) | 2004-10-13 | 2007-10-10 | Neurosearch Sweden Ab | Proceso para la sintesis de 4-(3-sulfonil)-piperidinas. |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| LT2667715T (lt) * | 2011-01-27 | 2017-11-10 | Neuren Pharmaceuticals Limited | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| MX2015003812A (es) * | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| SMT202600016T1 (it) | 2019-06-12 | 2026-03-09 | Prilenia Neurotherapeutics Ltd | Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi |
-
2018
- 2018-01-18 ES ES18741607T patent/ES2972205T3/es active Active
- 2018-01-18 IL IL268125A patent/IL268125B2/en unknown
- 2018-01-18 DK DK18741607.8T patent/DK3570940T3/da active
- 2018-01-18 BR BR112019015000-5A patent/BR112019015000A2/pt not_active Application Discontinuation
- 2018-01-18 CN CN201880007913.2A patent/CN110505902B/zh active Active
- 2018-01-18 CA CA3050700A patent/CA3050700C/en active Active
- 2018-01-18 AU AU2018210145A patent/AU2018210145B2/en active Active
- 2018-01-18 EP EP18741607.8A patent/EP3570940B1/en active Active
- 2018-01-18 WO PCT/US2018/014169 patent/WO2018136600A1/en not_active Ceased
- 2018-01-18 PL PL18741607.8T patent/PL3570940T3/pl unknown
- 2018-01-18 JP JP2019539958A patent/JP7114604B2/ja active Active
- 2018-01-18 HU HUE18741607A patent/HUE068300T2/hu unknown
-
2019
- 2019-07-17 US US16/514,167 patent/US11234973B2/en active Active
-
2022
- 2022-01-31 US US17/588,403 patent/US12551474B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190336488A1 (en) | 2019-11-07 |
| CA3050700C (en) | 2023-10-03 |
| ES2972205T3 (es) | 2024-06-11 |
| EP3570940B1 (en) | 2023-12-13 |
| CN110505902A (zh) | 2019-11-26 |
| IL268125B (en) | 2022-12-01 |
| WO2018136600A1 (en) | 2018-07-26 |
| US20220202798A1 (en) | 2022-06-30 |
| EP3570940A4 (en) | 2020-10-28 |
| IL268125A (en) | 2019-09-26 |
| CN110505902B (zh) | 2022-11-11 |
| BR112019015000A2 (pt) | 2020-04-07 |
| AU2018210145A1 (en) | 2019-08-29 |
| EP3570940A1 (en) | 2019-11-27 |
| HUE068300T2 (hu) | 2024-12-28 |
| JP7114604B2 (ja) | 2022-08-08 |
| CA3050700A1 (en) | 2018-07-26 |
| US12551474B2 (en) | 2026-02-17 |
| JP2020514313A (ja) | 2020-05-21 |
| US11234973B2 (en) | 2022-02-01 |
| DK3570940T3 (da) | 2024-02-19 |
| IL268125B2 (en) | 2023-04-01 |
| AU2018210145B2 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273495A (en) | Treatment of fragile X syndrome with cannabidiol | |
| HUE068300T2 (hu) | Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| IL258972A (en) | Thin and flexible absorbent items | |
| IL250016A0 (en) | Antisense oligonucleotides for the treatment of type 2 syndrome | |
| IL258962A (en) | Thin and flexible absorbent items | |
| GB2574762B (en) | Absorbent article | |
| GB201621480D0 (en) | Use of cannabinoids in the treatment of angelman syndrome | |
| IL258963A (en) | Thin and flexible absorbent items | |
| GB2606121B (en) | Thong-style absorbent article | |
| IL277993A (en) | Evaluation, composition and combined treatment of fragile X syndrome | |
| SG11202004898VA (en) | Underpants-shaped absorbent article | |
| GB2581058B (en) | Absorbent article | |
| GB2581054B (en) | Absorbent article | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| PL3716927T3 (pl) | Wyrób chłonny | |
| SG11202000921XA (en) | Absorbent article | |
| PL3691592T3 (pl) | Wyrób chłonny | |
| HUE066511T2 (hu) | Készítmények hunter-szindróma kezelésére | |
| ZA202003100B (en) | Absorbent article component | |
| GB202017373D0 (en) | Absorbent article | |
| GB2581084B (en) | Absorbent article | |
| GB2581601B (en) | Absorbent article | |
| GB202016461D0 (en) | Absorbent article | |
| SG11202000922VA (en) | Absorbent article |